Learn More
BACKGROUND Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because of an increased risk of death and cardiac events in patients(More)
Theresa M. Beckie, PhD; Cheryl Bushnell, MD, MHS, FAHA; Jeanine D’Armiento, MD, PhD; Penny M. Kris-Etherton, PhD, RD; Jing Fang, MD, MS; Theodore G. Ganiats, MD; Antoinette S. Gomes, MD; Clarisa R. Gracia, MD, MSCE; Constance K. Haan, MD, MS; Elizabeth A. Jackson, MD, MPH; Debra R. Judelson, MD; Ellie Kelepouris, MD, FAHA; Carl J. Lavie, MD; Anne Moore,(More)
Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC) consensus statement on secondary prevention,1 important evidence from clinical trials has emerged that further supports and broadens the merits of aggressive risk-reduction therapies for patients with established coronary and other atherosclerotic vascular(More)
Expert Panel/Writing Group* Lori Mosca, MD, PhD (Chair); Lawrence J. Appel, MD; Emelia J. Benjamin, MD; Kathy Berra, MSN, ANP; Nisha Chandra-Strobos, MD; Rosalind P. Fabunmi, PhD; Deborah Grady, MD, MPH; Constance K. Haan, MD ; Sharonne N. Hayes, MD; Debra R. Judelson, MD; Nora L. Keenan, PhD; Patrick McBride, MD, MPH; Suzanne Oparil, MD; Pamela Ouyang, MD;(More)
BACKGROUND The effect of raloxifene, a selective estrogen-receptor modulator, on coronary heart disease (CHD) and breast cancer is not established. METHODS We randomly assigned 10,101 postmenopausal women (mean age, 67.5 years) with CHD or multiple risk factors for CHD to 60 mg of raloxifene daily or placebo and followed them for a median of 5.6 years.(More)
Stroke ranks as the third leading cause of death in the United States. It is now estimated that there are more than 700 000 incident strokes annually and 4.4 million stroke survivors.1,2 The economic burden of stroke was estimated by the American Heart Association to be $51 billion (direct and indirect costs) in 1999.3 Despite the advent of treatment of(More)
A workshop was held September 27 through 29, 1999, to address issues relating to national trends in mortality and morbidity from cardiovascular diseases; the apparent slowing of declines in mortality from cardiovascular diseases; levels and trends in risk factors for cardiovascular diseases; disparities in cardiovascular diseases by race/ethnicity,(More)
Donald M. Lloyd-Jones, Margo Minissian, Lori Mosca, Eric D. Peterson, Ralph L. Sacco, John Barry A. Franklin, Raymond J. Gibbons, Scott M. Grundy, Loren F. Hiratzka, Daniel W. Jones, Sidney C. Smith, Jr, Emelia J. Benjamin, Robert O. Bonow, Lynne T. Braun, Mark A. Creager, the American Heart Association and American College of Cardiology Foundation Coronary(More)
Lori Mosca, MD, MPH, PhD, Chair; Carole L. Banka, PhD; Emelia J. Benjamin, MD; Kathy Berra, MSN, NP; Cheryl Bushnell, MD; Rowena J. Dolor, MD, MHS; Theodore G. Ganiats, MD; Antoinette S. Gomes, MD; Heather L. Gornik, MD, MHS; Clarissa Gracia, MD, MSCE; Martha Gulati, MD, MS; Constance K. Haan, MD; Debra R. Judelson, MD; Nora Keenan, PhD; Ellie Kelepouris,(More)
BACKGROUND There is growing awareness of cardiovascular disease (CVD) as the leading cause of death in women, but whether this greater awareness is associated with increased action by women to lower their personal or family's risk is unknown. METHODS AND RESULTS A nationally representative sample of 1008 women selected through random-digit dialing were(More)